Comera Life Sciences Announces Collaboration with Quality
– Ownership of proprietary sourcing for U.S.-manufactured lead SQore excipients allows for full control over supply chain and greater flexibility to...
Source: globenewswire.com
Page 3 - Jon Yu News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jon Yu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jon Yu Today - Breaking & Trending Today
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients
Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s...
Source: marketscreener.com
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease
UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further cl...
Source: marketscreener.com
Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights
- Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company - - Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab),
Source: finanznachrichten.de
Vaxxinity Reports First Quarter 2023 Financial Results and
CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...
Source: globenewswire.com